5,6-epoxy-5,6-dihydro-β,β-carotene | 1923-89-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 5,6-epoxy-5,6-dihydro-β,β-carotene
• 英文别名: β,β-carotene monoepoxide；β,β-carotene-5,6-epoxide；trans-5,6-expoxy-β-carotene；5,6-epoxy-β-carotene；β-carotene epoxide；(5Ξ,6Ξ)-5,6-epoxy-5,6-dihydro-β,β-carotene；beta-Carotene 5,6-epoxide；2,2,6-trimethyl-1-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohexen-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-7-oxabicyclo[4.1.0]heptane
• CAS: 1923-89-3
• 化学式: C₄₀H₅₆O
• 分子量: 552.884
• InChiKey: RVCRIPILOFSMFG-WWSVUWEKSA-N

物化性质

• 沸点：
  649.6±24.0 °C(Predicted)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  12.7
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6-epoxy-5,6-dihydro-β,β-carotene 在 盐酸 、 氯仿 作用下， 生成 mutatochrome
  参考文献：
  名称：

  β-胡萝卜素氧化物：β-胡萝卜素单环氧，β-胡萝卜素二环氧，Mutatochrom，Aurochrom，Luteochrom

  摘要：

  DOI：

  10.1002/hlca.660280158
• 作为产物：
  描述：

  β-胡萝卜素 在 双(2-甲基-3-呋喃基)二硫 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 5,6-epoxy-5,6-dihydro-β,β-carotene
  参考文献：
  名称：

  UVA照射下含氧硫风味分子对β-胡萝卜素稳定性的影响

  摘要：

  研究了11种含氧硫风味分子对乙醇体系中UVA照射下β-胡萝卜素稳定性的影响。研究了硫化物对β-胡萝卜素动态降解的影响以及结构与作用的关系。还鉴定了在 UVA 照射下硫化物加速的 β-胡萝卜素的氧化产物。结果表明，二硫化物对β-胡萝卜素光降解的加速作用比单硫化物更明显。β-胡萝卜素在甲基（2-甲基-3-呋喃基）二硫化物（MMFDS）、甲基糠基二硫化物（MFDS）和双（2-甲基-3-呋喃基）二硫化物（BMFDS）暴露后的降解遵循一级动力学。含呋喃硫化物如 MMFDS 和 BMFDS 表现出比其相应异构体更显着的加速作用。氧化产物被鉴定为 13-cis-β-carotene、9,13-di-cis-β-carotene 和 all-trans-5,6-epoxy-β-carotene。这些结果表明，含氧硫化物中的硫原子数和呋喃基团在 β-胡萝卜素的光氧化中起着关键作用。

  DOI：

  10.3390/molecules24020318

文献信息

• Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050004235A1

  公开（公告）日：2005-01-06

  A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

  一种治疗主体肝病的方法。该方法可能包括向主体施用有效量的药学上可接受的配方。药学上可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯烃。共轭聚烯烃可能包括至少一个取代基的无环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。
• Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050009758A1

  公开（公告）日：2005-01-13

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an at least partially water soluble carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种抑制和/或改善与主体中的活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病发生的方法，其中向主体施用类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类似物或衍生物的施用使得主体发生与活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病的风险可能降低。类似物或类似物组合可用于抑制和/或改善涉及活性氧化物种、活性氮物种、自由基和/或非自由基产生的任何疾病。在某些实施例中，该发明可能包括一种包括至少部分水溶性类胡萝卜素类似物或衍生物的化合物。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。该取代基可能通过醚功能基与环状环相耦合。
• Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
  申请人：Lockwood Fournier Samuel

  公开号：US20050049248A1

  公开（公告）日：2005-03-03

  A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种控制（例如，影响或影响）主体中C-反应蛋白水平的方法可能包括向主体施用有效量的药用可接受的配方。药用可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。取代基可能通过醚功能与环状环偶联。
• Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050065096A1

  公开（公告）日：2005-03-24

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.

  一种用于抑制和/或改善与活性氧化物种、活性氮物种、自由基和/或非自由基有关的疾病发生的方法，其中向受试者施用类胡萝卜素类似物或衍生物，可以单独使用或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合使用。类似物或衍生物的施用使得受试者发生与活性氧化物种、活性氮物种、自由基和/或非自由基有关的疾病的风险可能会降低。类似物或类似物组合可以用于抑制和/或改善涉及活性氧化物种、活性氮物种、自由基和/或非自由基产生的任何疾病。在某些实施例中，该发明可能包括包括类胡萝卜素类似物或衍生物的药物组合物。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。取代基可能通过醚功能基与环状环相结合。在某些实施例中，药物组合物可能包括生物学上不活性的载体。药物组合物可能适用于向人类受试者施用。
• Carotenoid analogs or derivatives for the inhibition and amelioration of disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050113372A1

  公开（公告）日：2005-05-26

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

  一种用于抑制和/或改善与反应性氧化物种、反应性氮物种、自由基和/或非自由基相关疾病发生的方法，其中向受试者施用类胡萝卜素类似物或衍生物，可以单独使用或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合使用。类似物或衍生物的施用使得受试者发生与反应性氧化物种、反应性氮物种、自由基和/或非自由基相关疾病的风险可能会降低。类似物或类似物组合可用于抑制和/或改善涉及反应性氧化物种、反应性氮物种、自由基和/或非自由基产生的任何疾病。在某些实施例中，该发明可能包括包含类胡萝卜素类似物或衍生物的化合物。类胡萝卜素类似物或衍生物可能是合成的。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括至少一个取代基的非环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。取代基可能增强类胡萝卜素类似物或衍生物的溶解性，使得类胡萝卜素类似物或衍生物至少部分溶解在水中。